Myelodysplastic Syndrome (MDS) Clinical Trial Tracker — Monitor New MDS Treatment Trials

Why MDS trial monitoring matters in 2026

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders affecting approximately 87,000 Americans annually, with a median age of diagnosis of 76 years. MDS ranges from low-risk disease (managed with transfusion support and growth factors) to high-risk MDS that often progresses to acute myeloid leukemia (AML) — and represents one of hematology's most active development areas.

The MDS clinical pipeline in 2026 is being shaped by several key forces:

• HMA combinations — azacitidine (Vidaza) and decitabine remain the backbone, but combinations with venetoclax, magrolimab, and IDH inhibitors are now standard Phase 2/3 approaches. The space is crowded with HMA+X programs
• TP53-mutant MDS — TP53-mutant MDS/AML is a high-need subtype with poor prognosis. APR-246 (eprenetapopt) had a high-profile Phase 3 failure; next-gen TP53 reactivators and MDM2 inhibitors continue entering trials
• Splicing factor mutations — SF3B1-mutant MDS is the most common mutational subtype in lower-risk MDS. H3B-8800 and other splicing modulators targeting this vulnerability are in development
• Erythroid maturation agents — luspatercept (Reblozyl) is now approved for lower-risk MDS; next-gen TGF-β pathway agents and EPOR agonists pursuing differentiated profiles
• CD47 "don't eat me" signal — magrolimab (anti-CD47) was in multiple MDS/AML programs; the CD47 mechanism is being explored with next-gen agents
• Allogeneic HSCT optimization — reduced-intensity conditioning, post-transplant maintenance with HMAs or targeted agents — a major area of investigator-initiated and industry-sponsored trials

What we monitor for MDS

Our system pulls from the ClinicalTrials.gov API every day. For an MDS watch profile, you can configure alerts for:

• Condition keywords: "myelodysplastic syndrome", "MDS", "myelodysplasia", "refractory anemia", "RAEB", "CMML", "del(5q)", "MDS/AML"
• Drug/target keywords: "azacitidine", "decitabine", "luspatercept", "venetoclax MDS", "magrolimab", "SF3B1", "TP53 MDS", "splicing factor" — any drug or target you're following
• Phase filter: Phase 1/2 for early competitive intelligence, Phase 3 for near-term commercial positioning
• Sponsor type: Industry, cooperative groups (ECOG-ACRIN, Alliance), academic, or all
• Status changes: New registrations, enrollment opens, status updates, and results postings

The MDS competitive landscape

MDS drug development is characterized by a high failure rate and a complex molecular taxonomy that makes patient selection difficult. Key competitive dynamics:

• Lower-risk MDS: Luspatercept (SF3B1-mutant) and lenalidomide (del[5q]) address specific subtypes. Gaps remain in non-SF3B1 lower-risk MDS, creating opportunity for pipeline programs
• Higher-risk MDS: HMA alone remains standard; venetoclax combinations and novel doublets are the active battleground. The AML/MDS overlap means many AML trials enroll MDS patients
• Post-HMA failure: An almost completely unmet need — very few approved options after HMA failure. Multiple programs targeting this population
• Transplant-eligible higher-risk MDS: Bridge-to-transplant strategies and post-transplant maintenance represent growing trial categories

MDS and AML share many molecular targets and many trial registrations enroll both. Monitoring new MDS-specific and AML/MDS trials captures the full competitive picture.

Who uses MDS clinical trial monitoring

• Hematology BD teams — tracking HMA combination, splicing, and TP53-targeted competitor programs
• Hematology investors — monitoring Phase 2/3 initiations and readouts in the MDS/AML space
• Hematologists and bone marrow transplant physicians — staying current on available trials for patients with higher-risk or post-HMA MDS
• Academic cooperative group researchers — following industry programs and identifying gaps for investigator-initiated studies
• CROs with hematology/oncology expertise — tracking enrollment competition across active MDS Phase 3 programs

How TrialNotify works

We run a direct API connection to ClinicalTrials.gov every morning, collecting all new and updated trials. Our matching engine compares each trial against your profile — condition keywords, drug targets, phase, sponsor type, and study status. Only relevant trials reach your inbox.

Your daily digest includes: trial title, phase, sponsor, current status, enrollment target, primary endpoint, and a direct link to the ClinicalTrials.gov record. No noise, no duplicate alerts.

Pricing

Free: 1 disease/keyword profile, daily email digest, ClinicalTrials.gov monitoring. No credit card required.

Starter — $49/month: 5 disease/keyword profiles, daily digest, phase and sponsor filters.

Pro — $149/month: Unlimited profiles, priority email delivery, digest frequency options. Best for BD teams and investors.